September 2007 Br J Cardiol 2007;14:190
Deepak L Bhatt, P Gabriel Steg
In this larger context, the international Reduction of Atherothrombosis for Continued Health (REACH) Registry was launched in order to study outcomes of atherothrombotic disease, risk factors for atherothrombosis, and also current treatment patterns. Already, the REACH Registry has provided insights at a global level.1 For example, under-treatment of common risk factors such as hypertension, hyperlipidaemia, and diabetes was observed in all regions included in the REACH Registry. Obesity, including morbid obesity, was highly prevalent. Multivascular disease – atherothrombosis affecting more than one arterial territory – was present in app
September 2007 Br J Cardiol 2007;14:215-218
Jonathan M Morrell, George C Kassianos
As with the global results, there was a high use of evidence-based therapies in the UK patients. Despite this, the combined incidence of cardiovascular events at one year (cardiovascular death, myocardial infarction, stroke) was high at 4.82%, 4.46% and 4.35% respectively for peripheral arterial disease (PAD), cerebrovascular disease (CVD) and coronary artery disease (CAD). These figures increase markedly when hospitalisations are taken into account, particularly in patients with PAD (18.54%) compared with CVD (8.29%) and CAD (10.07%). Cardiovascular event rates increased significantly with the number of symptomatic locations (p=0.0043), incr
September 2007 Br J Cardiol 2007;14(Suppl 3):S2-S16
No content available
May 2007 Br J Cardiol 2007;14:153-59
Jonathan M Morrell, George C Kassianos For The Reach Registry Investigators
No content available
March 2006 Br J Cardiol 2006;13:90-8
BJCardio editorial team
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits